This nanoparticle consists of a Fab fragment attached to a PEG. The FDA approved it in 2008, and it is used in treating many patients such as ankylosing spondylitis, Crohn’s disease, and psoriatic arthritis. This nano-system explicitly attacks the TNF-α through its protein part and leads to the inhibition. Here, TNF is linked to psoriatic arthritis.